EBS - Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process
2024-07-15 06:28:12 ET
Summary
- Emergent BioSolutions is a commercial stage company focused on developing vaccines and therapeutics to protect against public health threats worldwide.
- The company experienced a steep decline in stock value due to manufacturing mishaps and scandal during the pandemic, but is now recovering under new CEO Joseph Papa.
- Despite recent revenue stabilization and positive prospects, investors should approach Emergent with caution.
This is my first Emergent BioSolutions ( EBS ) article. Emergent is an interesting company; it differs from the usual small biotechs that I cover. It is very much a commercial state company. Its website lists its mission is to:
Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process...develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared, just in case they ever do. We do what we do because we see the opportunity to create a better, more secure world. One where preparedness empowers protection from the threats we face. And peace of mind prevails.